Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis
Open Access
- 5 January 2010
- journal article
- research article
- Published by Springer Nature in Neuroradiology
- Vol. 52 (10) , 875-881
Abstract
Introduction Cerebral atrophy is a compound measure of the neurodegenerative component of multiple sclerosis (MS) and a conceivable outcome measure for clinical trials monitoring the effect of neuroprotective agents. In this study, we evaluate the rate of cerebral atrophy in a 6-month period, investigate the predictive and explanatory value of other magnetic resonance imaging (MRI) measures in relation to cerebral atrophy, and determine sample sizes for future short-term clinical trials using cerebral atrophy as primary outcome measure. Methods One hundred thirty-five relapsing–remitting multiple sclerosis patients underwent six monthly MRI scans from which the percentage brain volume change (PBVC) and the number and volume of gadolinium (Gd)-enhancing lesions, T2 lesions, and persistent black holes (PBH) were determined. By means of multiple linear regression analysis, the relationship between focal MRI variables and PBVC was assessed. Sample size calculations were performed for all patients and subgroups selected for enhancement or a high T2 lesion load at baseline. Results A significant atrophy occurred over 6 months (PBVC = −0.33%, SE = 0.061, p < 0.0001). The number of baseline T2 lesions (p = 0.024), the on-study Gd-enhancing lesion volume (p = 0.044), and the number of on-study PBHs (p = 0.003) were associated with an increased rate of atrophy. For a 50% decrease in rate of atrophy, the sample size calculations showed that approximately 283 patients per arm are required in an unselected sampled population and 185 patients per arm are required in a selected population. Conclusion Within a 6-month period, significant atrophy can be detected and on-study associations of PBVC and PBHs emphasizes axonal loss to be a driving mechanism. Application as primary outcome measure in short-term clinical trials with feasible sample size requires a potent drug to obtain sufficient power.Keywords
This publication has 22 references indexed in Scilit:
- Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosisNeurology, 2009
- Persistent T1 hypointensity as an MRI marker for treatment efficacy in multiple sclerosisMultiple Sclerosis Journal, 2008
- Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: Sample size estimatesJournal of Neurology, 2007
- Short-term brain atrophy changes in relapsing–remitting multiple sclerosisJournal of the Neurological Sciences, 2004
- Atrophy Is Detectable Within a 3-Month Period in Untreated Patients With Active Relapsing Remitting Multiple SclerosisArchives of Neurology, 2003
- MR correlates of cerebral atrophy in patients with multiple sclerosisJournal of Neurology, 2002
- Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patientsMultiple Sclerosis Journal, 2000
- Brain atrophy in relapsing-remitting multiple sclerosis: relationship with ‘black holes’, disease duration and clinical disabilityJournal of the Neurological Sciences, 2000
- Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MSNeurology, 1999
- Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosisAnnals of Neurology, 1996